Endocrine/metabolic

INDICATION: Cushing disease

Patient sample and cell culture studies suggest the BRAF V600E inhibitor Zelboraf vemurafenib

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE